Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

COVID-19

Clinical and regulatory intelligence for COVID-19 with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
11
Catalysts
0
Assets
11

Relevant assets

Analysis →
AZD7442 →
baricitinib →
Boehringer →
COVAC-2 →
COVID-19 Symptoms →
Economic →
FDA →
Gohibic →
Ibuzatrelvir →
remdesivir →

Relevant companies

Boehringer Ingelheim →
Pfizer →

Recent signals(11)

CompetitiveJuly 29, 2026

LumiraDx UK Limited Evaluates POC Test for COVID-19 Symptoms

LumiraDx UK Limited is conducting a trial to evaluate a point-of-care test for COVID-19 using nasal and blood samples.

ClinicalJuly 14, 2026

DisCoVeRy Trial Evaluates AZD7442 for COVID-19 in Hospitalized Adults

The DisCoVeRy trial is now evaluating AZD7442 in hospitalized COVID-19 patients, comparing it to standard of care plus placebo.

ClinicalJuly 10, 2026

Pfizer's Ibuzatrelvir Study Targets High-Risk COVID-19 Patients

Pfizer is conducting a study to evaluate the safety and efficacy of ibuzatrelvir in non-hospitalized adults and adolescents with COVID-19 at risk of severe disease.

StrategyJuly 8, 2026

Economic Review of Nirmatrelvir/Ritonavir for COVID-19 Health Outcomes

The systematic literature review evaluates health-related outcomes of nirmatrelvir/ritonavir treatment for COVID-19.

ClinicalJuly 7, 2026

Boehringer Ingelheim's BI 764198 Trial Examines Formulation Impact on Bioavailability

The trial will assess the bioavailability of BI 764198 in different formulations and with food effects in healthy men.

RegulatoryJuly 7, 2026

FDA Authorizes Baricitinib and Remdesivir Combination for COVID-19 Treatment

The FDA has granted emergency use authorization for baricitinib combined with remdesivir for treating COVID-19 in hospitalized patients.

ClinicalJuly 7, 2026

FDA Warns of Drug Interaction Reducing Remdesivir Effectiveness in COVID-19 Treatment

The FDA has identified a potential drug interaction that may reduce the effectiveness of remdesivir, an authorized treatment for severe COVID-19.

RegulatoryJuly 7, 2026

FDA Authorizes Gohibic (vilobelimab) for COVID-19 Treatment

The FDA has authorized Gohibic (vilobelimab) injection for the treatment of COVID-19.

RegulatoryJuly 2, 2026

FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs

The HHS Secretary has determined that the emergency use authorizations for COVID-19 drugs will be terminated.

StrategyJune 20, 2026

Analysis of Oral Nirmatrelvir/Ritonavir Utilization in Spain for COVID-19

The analysis highlights the potential benefits of increasing oral nirmatrelvir/ritonavir use in outpatient settings for high-risk COVID-19 patients in Spain.

StrategyJune 13, 2026

COVAC-2 Vaccine Shows Safety and Immunogenicity as COVID-19 Booster in Phase 1 Trial

COVAC-2, a recombinant protein vaccine, demonstrated a favorable safety profile and strong immune responses as a booster in previously vaccinated adults.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

COVID-19 →
Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.